With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22795-99-9,(S)-(1-Ethylpyrrolidin-2-yl)methanamine,as a common compound, the synthetic route is as follows.
A mixture of 2-fluoro-5-(1-trityl-1H-benzotriazol-5-yl)-benzaldehyde (368 mg, 0.76 mmol), (S)-(+)-1-ethyl-2-aminomethylpyrrolidine (120 mg, 0.83 mmol) and molecular sieves in 10 mL of methanol was stirred at ambient temperature for 3 h. The mixture was cooled to -78¡ã C., and sodium borohydride (72 mg, 1.9 mmol) was added and the mixture was allowed to warm to room temperature and stirred overnight. The volatiles were removed in vacuo and the residue was diluted with dichloromethane and washed with water. The aqueous phase extracted with dichloromethane, and the combined organic phases were washed with brine, dried over magnesium sulfate, filtered and concentrated to leave the crude product. Chromatography (elution with methanol/dichloromethane) gave 255 mg of product., 22795-99-9
As the paragraph descriping shows that 22795-99-9 is playing an increasingly important role.
Reference£º
Patent; AVENTIS PHARMACEUTICALS INC.; US2008/138413; (2008); A1;,
Chiral Catalysts
Chiral catalysts – SlideShare